Status:
RECRUITING
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Lead Sponsor:
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Myelofibrosis
Eligibility:
All Genders
18-100 years
Brief Summary
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis...
Detailed Description
Myeloproliferative neoplasms (MPNs) are rare bone marrow disorders characterized by clonal proliferation of hematopoietic cell lineages, and include polycythemia vera (PV), essential thrombocythemia (...
Eligibility Criteria
Inclusion
- Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027
- Age ≥ 18 years
- Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives
Exclusion
- Diagnosis of early/prefibrotic primary myelofibrosis
- Concurrent participation to interventional clinical trials in MF
Key Trial Info
Start Date :
October 14 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
617 Patients enrolled
Trial Details
Trial ID
NCT06533813
Start Date
October 14 2024
End Date
December 31 2028
Last Update
December 26 2025
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Center after Prof.R.H. Yeolyan
Yerevan, Armenia
2
University of Copenhagen's Roskilde Hospital
Copenhagen, Denmark
3
Clinical Investigation Center of the Saint Louis Hospital
Paris, France
4
Internal Medicine C, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, University Medicine Greifswald
Greifswald, Germany